# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-25-003482
Filing Date
2025-03-21
Accepted
2025-03-21 17:15:59
Documents
84
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | anvs-20241231x10k.htm iXBRL | 10-K | 1844813
2 | EX-4.5 | anvs-20241231xex4d5.htm | EX-4.5 | 36188
3 | EX-19.1 | anvs-20241231xex19d1.htm | EX-19.1 | 37537
4 | EX-23.1 | anvs-20241231xex23d1.htm | EX-23.1 | 3859
5 | EX-31.1 | anvs-20241231xex31d1.htm | EX-31.1 | 12308
6 | EX-32.1 | anvs-20241231xex32d1.htm | EX-32.1 | 6209
7 | GRAPHIC | anvs-20241231x10k003.jpg | GRAPHIC | 28483
8 | GRAPHIC | anvs-20241231x10k004.jpg | GRAPHIC | 63085
9 | GRAPHIC | anvs-20241231x10k005.jpg | GRAPHIC | 66744
10 | GRAPHIC | anvs-20241231x10k006.jpg | GRAPHIC | 47205
11 | GRAPHIC | anvs-20241231x10k007.jpg | GRAPHIC | 28101
12 | GRAPHIC | anvs-20241231x10k008.jpg | GRAPHIC | 73556
13 | GRAPHIC | anvs-20241231x10k009.jpg | GRAPHIC | 109525
| Complete submission text file | 0001558370-25-003482.txt |  | 8591830

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
14 | EX-101.SCH | anvs-20241231.xsd | EX-101.SCH | 54070
15 | EX-101.CAL | anvs-20241231_cal.xml | EX-101.CAL | 43211
16 | EX-101.DEF | anvs-20241231_def.xml | EX-101.DEF | 179222
17 | EX-101.LAB | anvs-20241231_lab.xml | EX-101.LAB | 455975
18 | EX-101.PRE | anvs-20241231_pre.xml | EX-101.PRE | 343235
87 | EXTRACTED XBRL INSTANCE DOCUMENT | anvs-20241231x10k_htm.xml | XML | 1077961

Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39202 | Film No.: 25761547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)